Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011
Frontline pembrolizumab has consistent antitumor activity and safety in patients with advanced UC categorized as potentially ineligible for platinum-based chemotherapy, regardless of the variable definitions of platinum ineligibility used.
Authors
- Jakub Żołnierek (ORCID: https://orcid.org/0000-0003-2946-870X)
- Mahmut Gümüş (ORCID: https://orcid.org/0000-0003-3550-9993)
- Chinyere E. Okpara (ORCID: https://orcid.org/0000-0002-5621-9138)
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Peter H. O’Donnell (ORCID: https://orcid.org/0000-0003-2650-0049)
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Karen O’Hara
- Ronald de Wit (ORCID: https://orcid.org/0000-0002-1954-090X)
- Vagif Atduev (ORCID: https://orcid.org/0000-0003-4478-7282)
- Sang Joon Shin (ORCID: https://orcid.org/0000-0001-5350-7241)
- Burçak Karaca (ORCID: https://orcid.org/0000-0003-2638-1625)
- Se Hoon Park (ORCID: https://orcid.org/0000-0001-5084-9326)
- Arlene O. Siefker‐Radtke (ORCID: https://orcid.org/0000-0002-6328-9599)
- Tibor Csőszi (ORCID: https://orcid.org/0000-0002-7742-1968)
- Yujie Zhao (ORCID: https://orcid.org/0000-0003-2896-4955)
- Jacqueline Vuky (ORCID: https://orcid.org/0000-0001-5795-3361)
- Blanca Homet Moreno (ORCID: https://orcid.org/0000-0001-6712-8330)
- Thomas B. Powles (ORCID: https://orcid.org/0000-0001-7760-4724)
- Sonia Franco (ORCID: https://orcid.org/0000-0001-9202-0022)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Oregon Health & Science University (US)
- Queen Mary University of London (GB)
- Yonsei University (KR)
- University of Washington (US)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Samsung Medical Center (KR)
- University of Chicago (US)
- Ege University (TR)
- Fred Hutch Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- National Cancer Center Hospital East (JP)
- Eisai (United Kingdom) (GB)
- Erasmus MC Cancer Institute (NL)
- Istanbul Medeniyet University (TR)
- Federal Medical-Biological Agency (RU)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/cncr.35601
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57